Some Black women with hormone receptor (HR)-positive/HER2-negative breast cancer had worse outcomes compared with White women despite having similar genetic recurrence risk scores, according to data from the 2022 San Antonio Breast Cancer Symposium. Yara Abdou, MD, assistant professor at the University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center, presented results of an analysis of clinical outcomes respective to race and ethnicity in women enrolled in the RxPONDER trial. The trial aimed to assess the value of the 21-gene recurrence score (RS) in patients with ...
SABCS 2022
The San Antonio Breast Cancer Symposium (SABCS) is the largest and most prestigious scientific gathering on breast cancer research. Topics cover new treatments, patient care, surgical and reconstructive techniques, health equity, telemedicine, and more. Find highlights from the sessions that are most relevant to oncology nurses.
Advertisement
Results from the DESTINY-Breast03 study indicate survival advantage with the antibody drug conjugate.
The local recurrence rates were optimistic for women with multiple ipsilateral breast cancer in one clinical trial.
Advertisement
Kelly Pabst, MSN, APRN, ACNS-BC, AOCNS discusses early detection and prevention of lymphedema in breast cancer patients.
Linda Buck led a information session on sacituzumab govitecan-hziy at ONS 2023.
Accelerated approvals will no longer be granted based on overall response rates in single-arm trials.
The program resulted in high patient satisfaction, good compliance, and lower costs than traditional in-person visits.
In general, women preferred exercise partners with a similar diagnosis, location, age, and fitness goal.
The treatment group demonstrated increased quality of life, but did acupuncture affect myelosuppression?
